Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT

  • Andrea Varrone
  • Valeria Sansone
  • Maria Teresa Pellecchia
  • Marianna Amboni
  • Elena Salvatore
  • Giuseppe De Michele
  • Alessandro Filla
  • Paolo Barone
  • Sabina Pappatà
  • Marco Salvatore
Original Article

Abstract

Background

Dual-head SPECT systems are used by many clinical departments for [123I]FP-CIT SPECT imaging, while triple-head or brain-dedicated systems with better imaging performance are more commonly used by research institutions. There are limited data comparing the capability of the two types of system to measure dopamine transporter (DAT) loss in vivo.

Purpose

The aim of this study was to compare the ability of a dual-head and a brain-dedicated SPECT system to estimate the degree of DAT loss in different movement disorders with variable nigrostriatal impairment, with [123I]FP-CIT.

Materials and methods

Four patients with essential tremor, 24 with Parkinson’s disease (PD), six with spinocerebellar ataxia type 2 and six controls were studied with [123I]FP-CIT. SPECT scans were performed on a dual-head (E.CAM—Siemens) and subsequently on a brain-dedicated system (Ceraspect—DSI).

Results

Striatal DAT outcome measures on the E.CAM and the Ceraspect were strongly correlated and the putamen-to-caudate ratios were almost identical. Although the measured values were lower by 52 ± 25% in caudate and by 51 ± 31% in putamen on the E.CAM (p < 0.0001), the average striatal DAT decrease in each patient group compared with controls was similar for both systems. In PD patients, similar correlations (p < 0.05) were found between motor UPDRS or Hoehn and Yahr stage and striatal DAT density.

Conclusions

Despite underestimation of striatal DAT outcome measures, the E.CAM showed similar capability as the Ceraspect in measuring the degree of nigrostriatal dopaminergic deficit and assessing the correlation between DAT outcome measures and clinical variables of PD severity and stage.

Keywords

Gamma cameras Brain SPECT Neurodegenerative diseases Parkinson’s disease Dopamine transporters 

References

  1. 1.
    Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000;15:503–10.PubMedGoogle Scholar
  2. 2.
    Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord. 2004;19:1175–82.PubMedCrossRefGoogle Scholar
  3. 3.
    Eising EG, Muller TH, Freudenberg L, Muller SP, Dutschka K, Sonnenschein W, et al. SPECT imaging with [123I]-beta-CIT in Parkinsonism: comparison of SPECT images obtained by a single-headed and a three-headed gamma camera. Nucl Med Commun. 2001;22:145–50.PubMedCrossRefGoogle Scholar
  4. 4.
    Meyer PT, Sattler B, Lincke T, Seese A, Sabri O. Investigating dopaminergic neurotransmission with 123I-FP-CIT SPECT: comparability of modern SPECT systems. J Nucl Med. 2003;44:839–45.PubMedGoogle Scholar
  5. 5.
    Koch W, Radau PE, Munzing W, Tatsch K. Cross-camera comparison of SPECT measurements of a 3-D anthropomorphic basal ganglia phantom. Eur J Nucl Med Mol Imaging. 2006;33:495–502.PubMedCrossRefGoogle Scholar
  6. 6.
    Varrone A, Pellecchia MT, Amboni M, Sansone V, Salvatore E, Ghezzi D, et al. Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease. Neurology. 2004;63:2097–103.PubMedGoogle Scholar
  7. 7.
    Varrone A, Salvatore E, De Michele G, Barone P, Sansone V, Pellecchia MT, et al. Reduced striatal [123I]FP-CIT binding in SCA2 patients without parkinsonism. Ann Neurol. 2004;55:426–30.PubMedCrossRefGoogle Scholar
  8. 8.
    Louis ED, Ford B, Lee H, Andrews H, Cameron G. Diagnostic criteria for essential tremor: a population perspective. Arch Neurol. 1998;55:823–8.PubMedGoogle Scholar
  9. 9.
    Pellecchia MT, Varrone A, Annesi G, Amboni M, Cicarelli G, Sansone V, et al. Parkinsonism and essential tremor in a family with pseudo-dominant inheritance of PARK2: an FP-CIT SPECT study. Mov Disord. 2007;22:559–63.PubMedCrossRefGoogle Scholar
  10. 10.
    Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson’s disease by [123I]FPCIT SPECT. J Nucl Med. 1999;40:753–61.PubMedGoogle Scholar
  11. 11.
    Lee MS, Kim YD, Im JH, Kim HJ, Rinne JO, Bhatia KP. 123I-IPT brain SPECT study in essential tremor and Parkinson’s disease. Neurology. 1999;52:1422–6.PubMedGoogle Scholar
  12. 12.
    A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Parkinson study group. Neurology 2000;55:1540–7.Google Scholar
  13. 13.
    Booij J, Tissingh G, Winogrodzka A, Boer GJ, Stoof JC, Wolters EC, et al. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson’s disease. Eur J Nucl Med. 1997;24:68–71.PubMedCrossRefGoogle Scholar
  14. 14.
    Boesch SM, Donnemiller E, Muller J, Seppi K, Weirich-Schwaiger H, Poewe W, et al. Abnormalities of dopaminergic neurotransmission in SCA2: a combined 123I-betaCIT and 123I-IBZM SPECT study. Mov Disord. 2004;19:1320–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Andrea Varrone
    • 1
    • 4
  • Valeria Sansone
    • 1
  • Maria Teresa Pellecchia
    • 2
  • Marianna Amboni
    • 2
    • 3
  • Elena Salvatore
    • 2
  • Giuseppe De Michele
    • 2
  • Alessandro Filla
    • 2
  • Paolo Barone
    • 2
  • Sabina Pappatà
    • 1
  • Marco Salvatore
    • 1
  1. 1.Biostructure and Bioimaging Institute, National Research Council/Department of Biomorphological and Functional SciencesUniversity Federico IINapoliItaly
  2. 2.Department of Neurological SciencesUniversity Federico IINapoliItaly
  3. 3.IDC-HermitageNapoliItaly
  4. 4.Department of Clinical NeuroscienceKarolinska InstitutetStockholmSweden

Personalised recommendations